ReviewCurrent drug delivery2011
Radioimmunotherapy of solid tumors: searching for the right target.
Review in Current drug delivery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 62 citations in OpenAlex.
- 177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors.Molecular cancer therapeutics · 2025Article
- A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.Cancer · 2025Article
- Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review.Frontiers in oncology · 2024Review
- Enhanced Therapeutic Effects ofCancers · 2023Article
- Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy.Pharmaceutics · 2023Article
- The application of radionuclide therapy for breast cancer.Frontiers in nuclear medicine · 2023Review
- PSMA theragnostics for metastatic castration resistant prostate cancer.Translational oncology · 2022Article
- Article
- Radiopharmaceutical therapy in cancer: clinical advances and challenges.Nature reviews. Drug discovery · 2020Review
- B7-H3-targeted Radioimmunotherapy of Human Cancer.Current medicinal chemistry · 2020Review
- Cancer-associated mucins: role in immune modulation and metastasis.Cancer metastasis reviews · 2019Review
- Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.Molecular medicine (Cambridge, Mass.) · 2018Review
- Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2.EJNMMI research · 2016Article
- Mechanisms of action of therapeutic antibodies for cancer.Molecular immunology · 2015Review
- Rescue effects: irradiated cells helped by unirradiated bystander cells.International journal of molecular sciences · 2015Review
- Design, synthesis, and validation of Axl-targeted monoclonal antibody probe for microPET imaging in human lung cancer xenograft.Molecular pharmaceutics · 2014Article
- The development of immunoconjugates for targeted cancer therapy.Nature reviews. Clinical oncology · 2014Review
- Radiopharmaceutical therapy in the era of precision medicine.European journal of cancer (Oxford, England : 1990) · 2014Article
- Axl-targeted cancer imaging with humanized antibody h173.Molecular imaging and biology · 2014Article
- The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®.EJNMMI research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of ⁹⁰Y ibritumomab tiuxetan (Zevalin) and ¹³¹I Tositumomab (Bexxar) in treating non-Hodgkin's lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under pre-clinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.